FDAsafety guidance66% confidence
Rare Disease Drug Approvals
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Tadalafil; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This page describes recent rare disease drug approvals that received CDER or FDA communication. This is not an exhaustive list of all rare disease drug approvals.
Supporting Context
- Therapeutic area
- Urology · PDE5 Inhibitor
- Sub-indication
- General
Related signal: Jubilant Generics receives FDA approval for Tadalafil ANDA210329